FDA
-
-
-
-
-
-
-
OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD
-
-
-
-
-
-
-
OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain
-
-
-
-
-
-
-
OKYO Pharma receives FDA alignment on phase 2b/3 trial design
-
-
-
-
-
-
-
OKYO Pharma to Ring the Opening Bell at Nasdaq
-
-
-
-
-
-
-
OKYO Pharma Announces Chairman and Founder Acquires Shares
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on OKYO Pharma Ltd. (OKYO)
-
-
-
-
-
-
-
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain
-
326,716 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

